ClinicalTrials.gg
Not yet recruitingNCT07692659Updated Jul 13, 2026

Ultrasound-Guided Parasternal/Rectus Sheath Block vs Erector Spinae Plane Block for Pain Control in Cardiac Surgery

An interventional study of Parasternal/ Rectus sheath block and Erector spinae plane block in Analgesia, Perioperative Analgesia and Regional Block Technique, sponsored by National Cancer Institute, Egypt. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by National Cancer Institute, Egypt · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The researchers are working to improve recovery after heart surgery by reducing reliance on opioids. Newer regional anesthesia techniques can provide strong pain relief with fewer risks, but the choice of method depends on each patient's condition, medications, and surgical plan

Read the detailed description

Optimal anesthesia in cardiac surgery requires careful management to avoid sympathetic stimulation, with analgesia being central to patient safety and recovery. Traditionally, high-dose opioids were used, but this approach delays extubation, conflicting with fast-track protocols that emphasize early extubation. Consequently, opioid-free analgesia has gained importance, employing regional techniques such as neuraxial, paravertebral, and fascial plane blocks.

Thoracic epidural analgesia (TEA) offers effective pain control and reduces perioperative cardiovascular and respiratory complications. However, its use in anticoagulated patients raises concern for epidural hematoma. Alternatives like paravertebral and fascial plane blocks provide comparable analgesia with lower risk. The erector spinae plane block (ESPB) reduces analgesic requirements, though deep blocks still pose bleeding risks.

Superficial plane blocks are therefore clinically valuable. The parasternal intercostal block-targeting anterior cutaneous branches of intercostal nerves-has emerged as a safe option for patients undergoing median sternotomy while on anticoagulant or antiplatelet therapy. Additionally, bilateral rectus sheath block can reduce chest tube insertion pain after cardiac surgery.

02

Conditions studied

  • Analgesia
  • Perioperative Analgesia
  • Regional Block Technique

Keywords

  • Parasternal block; Rectus sheath block; ESPB; Analgesia
03

In context

Lead sponsor

National Cancer Institute, Egypt is the lead sponsor of 133 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both sexes,
  • patients
  • between 20- 35 kg/m2
  • adult patients above 18 years old will be included in the study

Exclusion criteria

Exclusion Criteria:

  • Patients with global hypokinesia
  • \< 40%
  • low count
  • coagulation impairment
  • deformity in the vertebral column
  • severe renal and hepatic impairment
  • any known allergy to the drugs used
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Parasternal/ Rectus sheath

    Patients will receive Parasternal and rectus sheath blocks; with injection of 10 ml bupivacaine 0.25% in each side after confirmation of needle position. Both parasternal and rectus heath blocks will be performed bilaterally

    Procedure: Parasternal/ Rectus sheath block

  • Experimental
    Erector Spinae Plane Block

    The patients will receive a bilateral ESPB with an injection of 20 ml of bupivacaine 0.25%.

    Procedure: Erector spinae plane block

Interventions

  • ProcedureParasternal/ Rectus sheath block

    the parasternal block will be performed parasternally at the level of fifth rib to the plane between the pectoralis major and the internal intercostal muscle. The rectus sheath block will be performed through injection in the plane posterior to the rectus abdominis muscle and anterior to the posterior rectus sheath

  • ProcedureErector spinae plane block

    injection above the transverse process

06

What researchers measure

Primary outcomes

  1. Numeric rating score

    postoperative pain scores using Numerical Rating Scale (NRS) with 0 meaning no pain and 10 meaning the worst pain level

    Time frame: 24 hours

Secondary outcomes

  1. postoperative opioid consumption

    opioid consumption in the first 24 hours postoperatively

    Time frame: 24 hours

  2. extubation time

    time to extubate

    Time frame: immediate postoperative

  3. first time to request analgesia

    first time to request opioid analgesia

    Time frame: 24 hours

  4. peri-operative hemodynamics

    incidence of hypotension, hypertension, tachycardia and bradycardia

    Time frame: intraoperative and 24 hours

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Jun 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Jul 9, 2026
StartEst.
Jul 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07692659
Collaborators
Saudi German Hospital - Madinah
Responsible party
Walaa Youssef Elsabeeny (Assistant professor of Anesthesia, Surgical Critical Care and Pain management, National Cancer Institute, Egypt) — Principal investigator
First posted
Jul 9, 2026
Start date
Jul 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jul 13, 2026

Study contacts

Walaa Y Elsabeeny, MD
Contact
walaa.elsabeeny@nci.cu.edu.eg
01007798466
Mostafa A Ibrahim, MD
Contact
MAbIbrahim@sghgroup.net
+966541227090
Walaa Y Elsabeeny, MD
principal investigator · A Professor of Anesthesia, Critical Care and Pain Management, National Cancer Institute, Cairo University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion